Intercept Pharmaceuticals (NASDAQ:ICPT) Given New $14.00 Price Target at Bank of America

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) had its price target cut by Bank of America from $17.00 to $14.00 in a report issued on Tuesday, The Fly reports.

Other analysts have also recently issued reports about the stock. HC Wainwright cut shares of Intercept Pharmaceuticals from a neutral rating to a sell rating and set a $8.00 target price for the company. in a report on Monday. SVB Securities increased their price objective on shares of Intercept Pharmaceuticals from $17.00 to $18.00 in a research report on Friday, March 3rd. Raymond James lowered shares of Intercept Pharmaceuticals from an outperform rating to a market perform rating in a report on Wednesday, May 17th. Royal Bank of Canada raised their price target on shares of Intercept Pharmaceuticals from $17.00 to $19.00 and gave the stock a sector perform rating in a research note on Friday, March 3rd. Finally, SVB Leerink boosted their price target on shares of Intercept Pharmaceuticals from $17.00 to $18.00 and gave the company a market perform rating in a report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of Hold and a consensus price target of $23.27.

Intercept Pharmaceuticals Trading Down 1.2 %

NASDAQ:ICPT opened at $9.42 on Tuesday. Intercept Pharmaceuticals has a one year low of $9.19 and a one year high of $21.86. The company has a debt-to-equity ratio of 3.32, a current ratio of 2.37 and a quick ratio of 2.37. The company’s 50-day simple moving average is $15.38 and its 200 day simple moving average is $16.03. The firm has a market capitalization of $392.72 million, a P/E ratio of 1.50 and a beta of 1.25.

Intercept Pharmaceuticals (NASDAQ:ICPT – Get Rating) last issued its earnings results on Thursday, March 2nd. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $77.22 million during the quarter, compared to the consensus estimate of $76.89 million. As a group, analysts forecast that Intercept Pharmaceuticals will post -1.68 EPS for the current fiscal year.

Institutional Trading of Intercept Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Pictet Asset Management SA raised its position in Intercept Pharmaceuticals by 16.4% during the third quarter. Pictet Asset Management SA now owns 183,106 shares of the biopharmaceutical company’s stock worth $2,554,000 after acquiring an additional 25,813 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Intercept Pharmaceuticals by 50.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 176,660 shares of the biopharmaceutical company’s stock valued at $2,185,000 after acquiring an additional 59,322 shares in the last quarter. Gladius Capital Management LP acquired a new stake in Intercept Pharmaceuticals during the fourth quarter worth approximately $32,000. Cheyne Capital Management UK LLP acquired a new stake in Intercept Pharmaceuticals during the fourth quarter worth approximately $327,000. Finally, Psagot Value Holdings Ltd. Israel acquired a new position in shares of Intercept Pharmaceuticals in the 4th quarter valued at $124,000. 81.09% of the stock is owned by hedge funds and other institutional investors.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia.